Potential and clinical translation of oncolytic measles viruses

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Introduction: Oncolytic viruses represent a novel treatment modality that is unencumbered by the standard resistance mechanisms limiting the therapeutic efficacy of conventional antineoplastic agents. Attenuated engineered measles virus strains derived from the Edmonston vaccine lineage have undergone extensive preclinical evaluation with significant antitumor activity observed in a broad range of preclinical tumoral models. These have laid the foundation for several clinical trials in both solid and hematologic malignancies, which have demonstrated safety, biologic activity and the ability to elicit antitumor immune responses. Areas covered: This review examines the published preclinical data which supported the clinical translation of this therapeutic platform, reviews the available clinical trial data and expands on ongoing phase II testing. It also looks at approaches to optimize clinical applicability and offers future perspectives. Expert opinion: Reverse genetic engineering has allowed the generation of oncolytic MV strains retargeted to increase viral tumor specificity, or armed with therapeutic and immunomodulatory genes in order to enhance anti-tumor efficacy. Continuous efforts focusing on exploring methods to overcome resistance pathways and determining optimal combinatorial strategies will facilitate further development of this encouraging antitumor strategy.

Original languageEnglish (US)
Pages (from-to)353-363
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume17
Issue number3
DOIs
StatePublished - Mar 4 2017

Fingerprint

Oncolytic Viruses
Measles virus
Viruses
Tumors
Genetic engineering
Clinical Trials
Antineoplastic Agents
Reverse Genetics
Gene Order
Genetic Engineering
Vaccines
Genes
Expert Testimony
Hematologic Neoplasms
Neoplasms
Testing
Therapeutics
Safety

Keywords

  • Edmonston
  • measles
  • MV-CEA
  • MV-NIS
  • oncolytic
  • Virotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Potential and clinical translation of oncolytic measles viruses. / Robinson, Steven; Galanis, Evanthia.

In: Expert Opinion on Biological Therapy, Vol. 17, No. 3, 04.03.2017, p. 353-363.

Research output: Contribution to journalReview article

@article{e4ae215dbd5844279a86307ce1179c8b,
title = "Potential and clinical translation of oncolytic measles viruses",
abstract = "Introduction: Oncolytic viruses represent a novel treatment modality that is unencumbered by the standard resistance mechanisms limiting the therapeutic efficacy of conventional antineoplastic agents. Attenuated engineered measles virus strains derived from the Edmonston vaccine lineage have undergone extensive preclinical evaluation with significant antitumor activity observed in a broad range of preclinical tumoral models. These have laid the foundation for several clinical trials in both solid and hematologic malignancies, which have demonstrated safety, biologic activity and the ability to elicit antitumor immune responses. Areas covered: This review examines the published preclinical data which supported the clinical translation of this therapeutic platform, reviews the available clinical trial data and expands on ongoing phase II testing. It also looks at approaches to optimize clinical applicability and offers future perspectives. Expert opinion: Reverse genetic engineering has allowed the generation of oncolytic MV strains retargeted to increase viral tumor specificity, or armed with therapeutic and immunomodulatory genes in order to enhance anti-tumor efficacy. Continuous efforts focusing on exploring methods to overcome resistance pathways and determining optimal combinatorial strategies will facilitate further development of this encouraging antitumor strategy.",
keywords = "Edmonston, measles, MV-CEA, MV-NIS, oncolytic, Virotherapy",
author = "Steven Robinson and Evanthia Galanis",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/14712598.2017.1288713",
language = "English (US)",
volume = "17",
pages = "353--363",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Potential and clinical translation of oncolytic measles viruses

AU - Robinson, Steven

AU - Galanis, Evanthia

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Introduction: Oncolytic viruses represent a novel treatment modality that is unencumbered by the standard resistance mechanisms limiting the therapeutic efficacy of conventional antineoplastic agents. Attenuated engineered measles virus strains derived from the Edmonston vaccine lineage have undergone extensive preclinical evaluation with significant antitumor activity observed in a broad range of preclinical tumoral models. These have laid the foundation for several clinical trials in both solid and hematologic malignancies, which have demonstrated safety, biologic activity and the ability to elicit antitumor immune responses. Areas covered: This review examines the published preclinical data which supported the clinical translation of this therapeutic platform, reviews the available clinical trial data and expands on ongoing phase II testing. It also looks at approaches to optimize clinical applicability and offers future perspectives. Expert opinion: Reverse genetic engineering has allowed the generation of oncolytic MV strains retargeted to increase viral tumor specificity, or armed with therapeutic and immunomodulatory genes in order to enhance anti-tumor efficacy. Continuous efforts focusing on exploring methods to overcome resistance pathways and determining optimal combinatorial strategies will facilitate further development of this encouraging antitumor strategy.

AB - Introduction: Oncolytic viruses represent a novel treatment modality that is unencumbered by the standard resistance mechanisms limiting the therapeutic efficacy of conventional antineoplastic agents. Attenuated engineered measles virus strains derived from the Edmonston vaccine lineage have undergone extensive preclinical evaluation with significant antitumor activity observed in a broad range of preclinical tumoral models. These have laid the foundation for several clinical trials in both solid and hematologic malignancies, which have demonstrated safety, biologic activity and the ability to elicit antitumor immune responses. Areas covered: This review examines the published preclinical data which supported the clinical translation of this therapeutic platform, reviews the available clinical trial data and expands on ongoing phase II testing. It also looks at approaches to optimize clinical applicability and offers future perspectives. Expert opinion: Reverse genetic engineering has allowed the generation of oncolytic MV strains retargeted to increase viral tumor specificity, or armed with therapeutic and immunomodulatory genes in order to enhance anti-tumor efficacy. Continuous efforts focusing on exploring methods to overcome resistance pathways and determining optimal combinatorial strategies will facilitate further development of this encouraging antitumor strategy.

KW - Edmonston

KW - measles

KW - MV-CEA

KW - MV-NIS

KW - oncolytic

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=85012981801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012981801&partnerID=8YFLogxK

U2 - 10.1080/14712598.2017.1288713

DO - 10.1080/14712598.2017.1288713

M3 - Review article

VL - 17

SP - 353

EP - 363

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 3

ER -